Citation Impact
Citing Papers
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers
2018 StandoutNobel
BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma
2017
A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis
2021 StandoutScienceNobel
The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2Hi Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors
2017
Cancer statistics, 2022
2022 Standout
Cancer statistics, 2023
2023 Standout
Regional Delivery of Chimeric Antigen Receptor–Engineered T Cells Effectively Targets HER2+ Breast Cancer Metastasis to the Brain
2017
Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again
2018 StandoutNobel
Current and emerging systemic therapies for cutaneous metastatic melanoma
2019
Dual HER2 Targeting with Trastuzumab and Liposomal-Encapsulated Doxorubicin (MM-302) Demonstrates Synergistic Antitumor Activity in Breast and Gastric Cancer
2016
The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications
2020 Standout
Cancer statistics, 2024
2024 Standout
Cancer treatment and survivorship statistics, 2022
2022 Standout
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
Engineering precision nanoparticles for drug delivery
2020 Standout
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
2019 Standout
Top 10 Challenges in Cancer Immunotherapy
2020
A view on drug resistance in cancer
2019 StandoutNature
Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials
2020
Cancer nanomedicine: progress, challenges and opportunities
2016 Standout
Pancreatic cancer
2020 Standout
Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies
2017 StandoutNobel
Targeting Ferroptosis to Iron Out Cancer
2019 Standout
Understanding the tumor immune microenvironment (TIME) for effective therapy
2018 Standout
A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1–insensitive models of triple-negative breast cancer
2018
Induction and differentiation of human induced pluripotent stem cells into functional cardiomyocytes on a compartmented monolayer of gelatin nanofibers
2016
Merkel cell carcinoma
2017
Delivery technologies for cancer immunotherapy
2019 Standout
Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity
2017 StandoutNobel
Immune checkpoint inhibitors in melanoma
2021
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2017 Standout
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Sex and gender: modifiers of health, disease, and medicine
2020 Standout
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Novel patterns of response under immunotherapy
2019
Targeting apoptosis in cancer therapy
2020 Standout
Immune checkpoint modulation: Rational design of combination strategies
2015
Broadening horizons: the role of ferroptosis in cancer
2021 Standout
Myasthenia gravis
2019 Standout
Role of PD-1 in Immunity and Diseases
2017 StandoutNobel
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
2023 Standout
Macrophages as regulators of tumour immunity and immunotherapy
2019 Standout
Tumour burden and efficacy of immune-checkpoint inhibitors
2021
Combination cancer immunotherapies tailored to the tumour microenvironment
2015
CAR-T cell therapy: current limitations and potential strategies
2021 Standout
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2019 Standout
Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives
2017
Targeting ferroptosis as a vulnerability in cancer
2022 Standout
Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM)
2017
Ferroptosis: mechanisms, biology and role in disease
2021 Standout
Immune checkpoint inhibitors: recent progress and potential biomarkers
2018 Standout
Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions
2017
Targeting immune cells for cancer therapy
2019
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress
2018
Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis
2018
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy
2023 StandoutNobel
Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer
2018 Standout
Electrospinning and Electrospun Nanofibers: Methods, Materials, and Applications
2019 Standout
Lipid Nanoparticles Delivering Constitutively Active STING mRNA to Stimulate Antitumor Immunity
2022 StandoutNobel
Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma
2018
A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG‐ACRIN Cancer Research Group (E2607)
2017
Human dendritic cells in cancer
2022
Diversity, Mechanisms, and Significance of Macrophage Plasticity
2019 Standout
Immune checkpoint inhibitors: therapeutic advances in melanoma.
2015
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
2018 Standout
Breast Cancer Treatment
2019 Standout
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
2018 StandoutNobel
Mature dendritic cells enriched in regulatory molecules may control regulatory T cells and the prognosis of head and neck cancer
2022 StandoutNobel
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma
2019
TISIDB: an integrated repository portal for tumor–immune system interactions
2019 Standout
Musculoskeletal and Rheumatic Diseases Induced by Immune Checkpoint Inhibitors: A Review of the Literature
2018
Cancer treatment and survivorship statistics, 2019
2019 Standout
Development of immune checkpoint therapy for cancer
2019
Combining anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) and -programmed cell death protein 1 (PD-1) agents for cancer immunotherapy
2021
CAR T cell immunotherapy for human cancer
2018 StandoutScience
Cancer immunotherapy using checkpoint blockade
2018 StandoutScience
Hyper-Progressive Disease: The Potential Role and Consequences of T-Regulatory Cells Foiling Anti-PD-1 Cancer Immunotherapy
2020 StandoutNobel
Works of Zeynep Eroglu being referenced
Clinical Features of Acquired Resistance to Anti–PD-1 Therapy in Advanced Melanoma
2017
Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy
2015
Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases
2021
Analysis of Circulating Tumor Cells in Breast Cancer
2013
Human Epidermal Growth Factor Receptor Family-Targeted Therapies in the Treatment of HER2-Overexpressing Breast Cancer
2014
Clinical outcomes in metastatic uveal melanoma treated with PD‐1 and PD‐L1 antibodies
2016
Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab
2015
Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy
2017
Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma
2018
Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction
2016
Targeting angiopoietin-2 signaling in cancer therapy
2013
Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma
2017
A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma
2016
Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma
2017
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
2016
Significant antitumor activity for low-dose ipilimumab (IPI) with pembrolizumab (PEMBRO) immediately following progression on PD1 Ab in melanoma (MEL) in a phase II trial.
2020
The efficacy of anti‐PD‐1 agents in acral and mucosal melanoma
2016
Long-Term Outcomes in Patients With BRAF V600–Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib
2017
Clinical Correlates of Response to Anti-PD-1–based Therapy in Patients With Metastatic Melanoma
2019